EUCTR2012-002067-10-NL
Active, not recruiting
Not Applicable
Mesenchymal stromal cells for treatment of drug resistantpediatric Juvenile idiopathic arthritis - MSC-JIA
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- niversity Medical Center Utrecht
- Status
- Active, not recruiting
- Last Updated
- 11 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •In order to be eligible to participate in this study, a subject must meet all of the following criteria: Patients (4\-18 years of age) diagnosed with juvenile idiopathic arthritis according to the ILAR\-criteria with active arthritis resistant to intra\-articular steroids and systemic use of methotrexate and for whom no on\-label indication exists for (not yet used) biologicals. The patient is followed for adverse events via the Pharmachild database.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 6
- •F.1\.2 Adults (18\-64 years) no
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) no
- •F.1\.3\.1 Number of subjects for this age range
Exclusion Criteria
- •Concurrent use of biological response modifiers.
- •Concurrent infection, febrile illness or malignancy.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Mesenchymal stromal cells for treatment of drug resistantpediatric juvenile idiopathic arthritisjuvenile idiopathic arthritisNL-OMON21350niversity Medical Center Utrecht6
Active, not recruiting
Not Applicable
Mesenchymal Stromal Cells (MSC) for the treatment of severe (grade II-IV) steroid-resistant Graft Versus Host Disease (GVHD): a phase I trial - MSC-GvHDGraft versus Host disease GvHD steroid resistantEUCTR2008-007869-23-ITAZIENDA OSPEDALIERA SAN GERARDO DI MONZA
Active, not recruiting
Not Applicable
se of mesenchymal cells for the treatment of patients with respiratory syndrome caused by new coronavirusRBR-3fz9yrPaulo Roberto Slud Brofman
Active, not recruiting
Not Applicable
Mesenchymal stem cell based therapy for the treatment of osteogenesis imperfectaOsteogenesis imperfecta (OI) is a rare genetic disorder with increased bone fragility of varying severity. In the majority of patients the disease is caused by mutations in collagen type I. Severe OI is characterized by osteopenia, frequent fractures, progressive deformity, short stature, loss of mobility, chronic pain and can lead to premature death. At present a cure does not exist.Therapeutic area: Body processes [G] - Cell Physiological Phenomena [G04]EUCTR2012-002553-38-ESItziar Astigarraga Aguirre
Terminated
Phase 1
se of mesenchymal stromal cells for Graft-versus-host disease after stem cell transplantatioGraft vs Host DiseaseT86.0RBR-7s99ksfHospital de Clínicas da Universidade Federal do Paraná - HCUFPR